Sandoz Doesn’t Need Biosimilars Purchases, Chief Tells Finanz

Novartis AG’s Sandoz unit doesn’t need acquisitions in the biosimilars business, Finanz und Wirtschaft reported, citing an interview with Jeff George, who heads the unit.

George said he expects a “shakeout” in the market as some smaller companies lack the technological abilities and commercial understanding needed to bring about sophisticated biosimilars, the newspaper reported.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE